Global Cell Line Development Market to witness growth of 8.7% from 2023 to 2028

Market Overview:

The Global Cell Line Development Market size was valued at USD 6.74 billion in 2021 and is projected to reach USD 12.09 billion by 2028, growing at a CAGR of 8.7% from 2022 to 2028.

Cell line development refers to the process of harnessing cellular machinery to create therapeutic biologics or desired proteins. This process can be accomplished using different expression systems, such as bacterial, plant-based, yeast, or mammalian systems. They are cultivated in suspension cultures and used in bioreactors during the manufacturing stage. In recent times, advancements in gene editing technologies, including zinc finger nucleases (ZFN), transcription activator-like effector nucleases (TALENs), and the CRISPR/Cas9 system, have significantly improved the precision and ease of designing cell lines to optimize the production of biotherapeutics.

Get a free sample -
https://introspectivemarketresearch.com/request/16126

Top Key Players Covered in Cell Line Development Market
• GE Healthcare
• Sartorious AG
• Corning Inc.
• WuXi AppTec Inc.
• Selexis SA
• Sigma-Aldrich Corporation
• Lonza Group AG
• Sartorius
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Merck KGaA
• Promega Corporation
• Beckman Coulter Inc.
• European Collection of Cell Cultures, and Other Major Players.

Market Dynamics:

Driver:
Cell lines are commonly employed in research as substitutes for primary cells due to the various advantages they offer. These advantages include cost-effectiveness, simplicity of use, an unlimited supply of material, and the ability to bypass ethical concerns associated with animal and human tissue usage. Their utilization has significantly transformed scientific research, finding applications in vaccine production, drug testing for metabolism and cytotoxicity, antibody production, gene function studies, the development of artificial tissues like synthetic skin, and the synthesis of therapeutic proteins.

Opportunities:

Cell Line Engineering (CLE) techniques are innovative approaches that involve obtaining human primary cells or animal cells from tissue sources, cultivating them in a three-dimensional environment using specialized media and allowing the cells to form spherical aggregates called spheroids. CLE is an advanced technology that enables companies to create customized cell lines using CRISPR products. This advancement is particularly beneficial for cancer cell research, the development of artificial organs, and the exploration of novel treatments, as it allows for a more accurate representation of living human tissues while minimizing the risks of contamination and uncontrolled mutations.

Market Segmentation

By Product
• Equipment
• Reagents & Media
• Accessories & Consumables

By Source
• Mammalian
• Non-Mammalian

By Cell Line Type
• Recombinant Cell Lines
• Hybridomas
• Continuous Cell Lines
• Primary Cell Lines

By Application
• Bioproduction
• Drug Discovery
• Toxicity Testing
• Tissue Engineering
• Research

Learn More on The Cell Line Development Market Report Here:
https://introspectivemarketresearch.com/reports/cell-line-development-market/#tab-responsive-2

Regional Analysis of the Cell Line Development Market
The North American region is anticipated to have the highest share of the cell line development market in the forecasted period. The growing prevalence of cancer and seasonal flu has promoted the usage of cell lines for developing innovative treatment methods. According to the American Cancer Society, 1.9 million new cancer cases are expected to be diagnosed in 2021. In 2021, an estimated 608,570 Americans will succumb to cancer, equating to approximately 1,670 deaths per day. Cancer is the second leading cause of death in the United States, trailing only heart disease. Human cancer-derived cell lines are basic models used in laboratories to study cancer biology and the therapeutic efficacy of anticancer agents.

By Region
• North America (US, Canada, Mexico)
• Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
• Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
• Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)
• Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
• South America (Brazil, Argentina, Rest of SA)

Segmentation Analysis of the Cell Line Development Market
By Product, the reagents & media segment is anticipated to have the highest share of the market over the analysis period. Reagents for cell culture are crucial to the success of physiologically relevant cell models in biomedical research and bioproduction.
By Source, the mammalian segment is expected to lead the growth of the cell line development market over the analysis period. Protein production in sufficient quantity and quality is a critical requirement. There has been a gradual increase in the use of mammalian cells for protein production.
By Type Of Cell Line, the recombinant cell line segment is anticipated to dominate the market in the projected period. One of humanity's most pressing needs is the mass production of therapeutic proteins for the treatment of diseases that affect millions of people.
By Application, the bioproduction segment is forecasted to have the highest share of the market. Protein therapeutics, which include monoclonal antibodies [mAbs], peptides, and recombinant proteins, is the biopharmaceutical industry's largest group of new products in development.

Key Industry Developments in Cell Line Development Market
In September 2022, Sartorius, a life science company, completed the acquisition of Albumedix Ltd. through its French-listed subsidiary Sartorius Stedim Biotech. Albumedix, based in Nottingham, UK, is a market leader in recombinant albumin-based solutions.
In July 2022, Granite Bio and ProBioGen joined forces to provide GMP manufacturing and cell line development services. Granite Bio's lead candidate for the treatment of autoimmune and specific cancer indications is a novel monoclonal antibody.
In January 2021, Thermo Fisher Scientific created a novel medium for the development and expansion of human T lymphocytes (T-cells) for cell therapy developers employing allogeneic workflows. The Gibco CTS OpTmizer Pro Serum-Free Media (SFM) is a first-of-its-kind media solution that addresses the metabolism of healthy donor cells, making it ideal for use in the creation of allogeneic, off-the-shelf cell treatments.

Table of content:-
Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
 3.1 By Product
 3.2 By Source
 3.3 By Cell Line Type
 3.4 By Application
Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing
Chapter 5: Cell Line Development Market by Product
To Be Continue…

Buy the Latest Version of this Report @
https://introspectivemarketresearch.com/inquiry/16126

Contact us:
Introspective Market Research
3001 S King Drive,
Chicago, Illinois
60616 USA
Ph no: +1 773 382 1049
Email: sales@introspectivemarketresearch.com

About us:
Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to assist our clients grow and have a successful impact on the market. Our team at IMR is ready to assist our clients flourish their business by offering strategies to gain success and monopoly in their respective fields. We are a global market research company, specialized in using big data and advanced analytics to show the bigger picture of the market trends. We help our clients to think differently and build better tomorrow for all of us. We are a technology-driven research company, we analyze extremely large sets of data to discover deeper insights and provide conclusive consulting. We not only provide intelligence solutions, but we help our clients in how they can achieve their goals.

This release was published on openPR.